With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate
In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched ye...
In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched yesterday afternoon with $30 million and an in-licensed, novel approach to treat idiopathic pulmonary fibrosis.